A capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae and its preparation method and application

By isolating and purifying the capsular polysaccharide of Klebsiella pneumoniae ST11-K64, the problem of low extraction efficiency was solved, and a highly efficient mouse sepsis model was induced for basic research on sepsis.

CN118726506BActive Publication Date: 2024-11-22NANJING UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411228037.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-22
Estimated Expiration
2044-09-03

AI Technical Summary

Technical Problem

Existing technologies for extracting capsular polysaccharides are difficult and have low extraction efficiency, making them unsuitable for effectively inducing sepsis mouse models.

Method used

Using ST11-K64 Klebsiella pneumoniae as the source, capsular polysaccharides were obtained through isolation and purification, including removal of lipopolysaccharides, surfactant extraction, ethanol precipitation, and dialysis purification, to obtain ST11-K64 Klebsiella pneumoniae capsular polysaccharides, which were used to induce a mouse sepsis model.

Benefits of technology

The efficient extraction of capsular polysaccharides from Klebsiella pneumoniae ST11-K64 was achieved, which can induce a mouse sepsis model and simulate the pathophysiological process of human sepsis, for use in basic research on sepsis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118726506B_ABST
    Figure CN118726506B_ABST
Patent Text Reader

Abstract

The invention discloses a capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae and a preparation method and application thereof, belonging to the field of biotechnology. The capsular polysaccharide of the invention is obtained by separating and purifying ST11-K64 type Klebsiella pneumoniae and the main chain of the molecular structure is →[6)-β-D-Manp-(1] 3 →[4)‑β‑D‑Glcp‑(1] 6 →, the four side chains are β-D-Rhap-(1→3)-β-D-Rhap-(1→, β-D-Manp-(1→, β-D-Glcp-(1→[3)-β-D-Glcp-(1]2→, β-D-Glcp-(1→, and the monosaccharide composition after uronic acid reduction is rhamnose, glucose, and mannose in a molar ratio of 0.200:0.583:0.217; and the preparation method of the polysaccharide component product is disclosed. The capsule polysaccharide component product of the present invention has the function of inducing a mouse sepsis model, and can be used as a sepsis animal model inducer in the field of basic sepsis research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae and a preparation method and application thereof. Background Art

[0002] Klebsiella pneumoniae is a common pathogenic microorganism in clinical infection. With the widespread use of antibiotics, the drug resistance of Klebsiella pneumoniae has gradually increased, and the frequency of multidrug-resistant strains has gradually increased. Among them, ST11-K64 Klebsiella pneumoniae has attracted widespread attention due to its high drug resistance and high virulence. Moreover, ST11-K64 Klebsiella pneumoniae infection is more common in the elderly, people with weakened immunity, and people with serious diseases. The severity of the infection varies, and severe cases can lead to severe symptoms such as sepsis, septicemia, and septic shock. Therefore, the treatment and prevention of clinical infection with ST11-K64 Klebsiella pneumoniae is a key issue that needs to be solved urgently.

[0003] Laboratory mice are widely regarded as the main animal model for studying the genetic or cellular system mechanisms associated with human diseases. The mouse sepsis model can simulate many phenotypes and disease progression of human sepsis, and is the key to the clinical translation of drugs and preventive measures. Currently, the commonly used methods include bacterial injection, intraperitoneal injection of lipopolysaccharide, and cecal ligation and puncture, all of which can induce physiological and pathological changes of human sepsis in mice, such as systemic inflammatory immune response and multi-organ tissue damage. Klebsiella pneumoniae is a common nosocomial infection strain in sepsis patients. Using the sepsis mouse model to study its induced physiological and pathological manifestations is expected to become a model for clinical sepsis prevention and treatment research.

[0004] Capsular polysaccharides, like lipopolysaccharides, are exopolysaccharides and are the main virulence factors of Klebsiella pneumoniae, with high research value. From the perspective of basic medicine, lipopolysaccharides are often used to induce sepsis mouse models. Further understanding of the mechanism of action of lipopolysaccharides will help develop targeted anti-infective drugs to inhibit the growth and reproduction of infected strains. There are few reports on the infection mechanism of Klebsiella pneumoniae through capsular polysaccharides. In recent years, there have been studies on immunotherapy of capsular polysaccharides, such as the use of antibodies or T cell receptors and other immune molecules to target and inhibit the activity of capsular polysaccharides, which also provides a new way to treat Klebsiella pneumoniae infection. Capsular polysaccharides have good immunogenicity and can induce the body to produce a protective immune response. The development of vaccines based on capsular polysaccharides has good application prospects. Therefore, a septic mouse model was established using capsular polysaccharides as inducers to study the interaction between this type of virulence factor and the host.

[0005] Currently, there is no relevant technology to develop capsular polysaccharides as inducers for sepsis mouse models, mainly because it is difficult to extract and enrich capsular polysaccharides, and capsular polysaccharides are usually present on the surface of microbial cells. They are easily affected by other components such as cell walls during the extraction process, resulting in low extraction efficiency. Summary of the invention

[0006] The present invention provides a capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae and a preparation method and application thereof, which solve the problems of difficult extraction process and low extraction efficiency of capsular polysaccharide in the prior art, and discloses the application of the capsular polysaccharide component and its structure in inducing a sepsis mouse model, which can be used for establishing a sepsis mouse model.

[0007] To achieve the above objectives, the present invention adopts the following technical solutions:

[0008] A capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae, which is obtained by separating and purifying ST11-K64 type Klebsiella pneumoniae, wherein the main chain of the molecular structure is →[6)-β-D-Manp-(1]3→[4)-β-D-Glcp-(1]6→, and the four side chains are

[0009] β-D-Rhap-(1→3)-β-D-Rhap-(1→, β-D-Manp-(1→, β-D-Glcp-(1→[3)-β-D-Glcp-(1]2→, β-D-Glcp-(1→, the monosaccharide composition after uronic acid reduction is rhamnose, glucose, and mannose in a molar ratio of 0.200:0.583:0.217.

[0010] The method for preparing the capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae comprises the following steps:

[0011] S1: The ST11-K64 type Klebsiella pneumoniae culture solution is cultured to a certain concentration, lipopolysaccharide is removed, and then centrifuged to obtain a precipitate;

[0012] S2: extracting the precipitate obtained in S1 with a surfactant and centrifuging to obtain a supernatant;

[0013] S3: remove proteins and impurities from the supernatant obtained in S2 and centrifuge to obtain the upper aqueous phase;

[0014] S4: The upper aqueous phase obtained in S3 is precipitated with ethanol and then the ethanol is removed; and then the capsular polysaccharide is obtained by separation and purification through dialysis.

[0015] In the above steps, the concentration of ST11-K64 Klebsiella pneumoniae culture solution in S1 was 1.0×10 9The number of bacteria / ml, the method of removing lipopolysaccharide is as follows: remove the culture medium from the culture solution that reaches a certain concentration, add an equal amount of 50mmol / L-100mmol / L EDTA, incubate at 37℃ for 30min-60min, centrifuge to remove the supernatant, and wash the precipitate with PBS buffer 3 times to remove lipopolysaccharide;

[0016] The surfactant used in S2 is 1% (w / v) 3-sulfopropyltetradecyl dimethyl betaine. The specific extraction process is as follows: the precipitate obtained in S1 is weighed, PBS is added at a solid-liquid ratio of 1:5 (mg / mL), and then 1 / 5 volume of 1% (w / v) methyl alkali is added, vortexed and mixed, and then incubated at 50°C for 30min-60min to extract capsular polysaccharides;

[0017] To remove proteins and impurities from S3, a chloroform-n-butanol (5:1) mixed solution was used for 1-3 times; the mixture was incubated in the dark for 30 min to remove proteins and impurities;

[0018] The ethanol precipitation in S4 is carried out by standing at 4°C for 48 hours to precipitate the capsular polysaccharide; the dialysis time is 48 hours, and the molecular weight cutoff of the dialysis bag is 8000-14000Da.

[0019] The capsular polysaccharide of ST11-K64 Klebsiella pneumoniae is used to prepare a mouse sepsis model. When used, 2 mg of the capsular polysaccharide dry powder is dissolved in 1 ml of PBS and mixed to obtain a 2 mg / ml solvent, which is conventionally stored at -20°C. Each mouse is intraperitoneally injected with 40 mg / kg of the solvent, and a mouse sepsis disease experimental model is obtained 12 hours later.

[0020] Beneficial effects: The present invention provides a capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae and a preparation method and application thereof. Compared with the prior art, the present invention has the following advantages:

[0021] The capsular polysaccharide component product of the present invention uses ST11-K64 type Klebsiella pneumoniae capsular polysaccharide as a raw material, is obtained by removing lipopolysaccharide, extracting with a surfactant, ethanol precipitation, removing protein impurities, and dialysis separation and purification, and the components and structure of the ST11-K64 type Klebsiella pneumoniae capsular polysaccharide are analyzed. The product is a natural extract with good biological activity. According to tests, the capsular polysaccharide of the present invention has the function of inducing a mouse sepsis model, can simulate the pathological and physiological process of the occurrence and development of human sepsis, and can be widely used in the field of basic research on sepsis as a novel biological inducer. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1It is the ST11-K64 type Klebsiella pneumoniae used in the embodiment of the present invention, wherein a is the scanning electron microscopy morphology of the strain (microscope 10000X); b is the transmission electron microscopy morphology of the strain (microscope 20000X).

[0023] Figure 2 It is the purity detection of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0024] Figure 3 It is the monosaccharide composition after uronic acid reduction of the purified capsular polysaccharide ST11-K64-CPS in the embodiment of the present invention.

[0025] Figure 4 It is one of the internal connection modes of the polysaccharide extracted from the capsular polysaccharide ST11-K64-CPS in the embodiment of the present invention.

[0026] Figure 5 This is the second internal connection mode of the polysaccharide extracted from the capsular polysaccharide ST11-K64-CPS in the embodiment of the present invention.

[0027] Figure 6 This is the third internal connection mode of the polysaccharide, which is the result of the analysis of the methylated sugar alcohol acetyl ester of the capsular polysaccharide ST11-K64-CPS extracted in the embodiment of the present invention.

[0028] Figure 7 This is the fourth internal connection mode of the polysaccharide, which is the result of analyzing the methylated sugar alcohol acetyl ester of the capsular polysaccharide ST11-K64-CPS extracted in the embodiment of the present invention.

[0029] Figure 8 This is one of the structural analyses of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0030] Fig. 9 This is the second structural analysis of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0031] Fig.10 This is the third structural analysis of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0032] Fig.11 This is the fourth structural analysis of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0033] Fig.12 This is the fifth structural analysis of the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0034] Fig.13This is the LD50 test result of the mouse sepsis model constructed with the capsular polysaccharide ST11-K64-CPS extracted in the examples of the present invention.

[0035] Fig.14 This is the result of detecting the inflammatory immune response of the mouse sepsis model constructed by using the capsular polysaccharide ST11-K64-CPS extracted in the example of the present invention.

[0036] Fig.15 This is the result of detecting organ and tissue damage in the mouse sepsis model constructed by using the capsular polysaccharide ST11-K64-CPS extracted in the example of the present invention. DETAILED DESCRIPTION

[0037] The technical solution of the present invention is described in detail below in conjunction with the accompanying drawings and specific implementation methods.

[0038] The present invention uses ST11-K64 Klebsiella pneumoniae. The ST11-K64 Klebsiella pneumoniae used in the embodiments of the present invention was obtained from the Department of Critical Care Medicine, Jinling Hospital Affiliated to Nanjing University Medical School ( Figure 1 ).

[0039] The mice used in the present invention are C57BL / 6J male mice, 5 to 6 weeks old, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.

[0040] The reagents used in the present invention include: mouse IL-1β ELISA kit, mouse IL-6 ELISA kit, mouse TNF-α ELISA kit (Shanghai Biyuntian Biotechnology Co., Ltd.); EDTA (Biyuntian Biotechnology Co., Ltd.); 3-sulfopropyl tetradecyl dimethyl betaine (Chengdu McCahey Chemical Co., Ltd.); chloroform, n-butanol, anhydrous ethanol (Sinopharm Chemical Reagent Co., Ltd.); methylation kit (Borui Saccharide); citric acid (Shanghai Aladdin Biochemical Technology Co., Ltd.); acetic anhydride, sodium hydroxide (Shanghai Testing); mannose, rhamnose, galacturonic acid, galactose, glucose, glucuronic acid, arabinose, xylose, fucose, glucosamine hydrochloride, N-acetyl-D-glucosamine, D-fructose, D-ribose, galactosamine hydrochloride, L-guluronic acid, D-mannuronic acid, 2-keto-3-deoxyoctanoic acid, phenol, concentrated sulfuric acid, etc., all of analytical grade.

[0041] The instruments and equipment used in the present invention include: ultra-micro spectrophotometer, constant temperature water bath, high performance liquid chromatograph, electronic balance, centrifuge, transmission electron microscope, ion chromatograph, rotary evaporator, nitrogen blower, magnetic stirrer, vacuum drying oven, gas-mass spectrometer, uronic acid reduction instrument, nuclear magnetic resonance instrument, freeze dryer, biological safety cabinet, high pressure steam sterilizer, Milli-Q IQ7003 water purifier. All experiments were repeated at least three times, and the data were expressed as mean ± SD. The statistical analysis of the data was analyzed by t-test or ANOVA, and p < 0.05 was considered to be statistically different.

[0042] Unless otherwise specified, other raw materials are selected from those known in the art, but do not limit the implementation of the present invention. Other reagents and equipment known in the art can be applied to the following embodiments.

[0043] Example 1

[0044] The Klebsiella pneumoniae strain used for identification was ST11-K64:

[0045] The genome sequence of the strain was obtained by whole genome sequencing, and the MLST typing of the strain was analyzed using mlst software (v38) with reference to the PubMLST database, and it was found to be ST11. Using the K-PAM online database, the wzi gene sequence in the genome sequence of the strain was entered into the prediction database, and the capsule type of the strain was identified as K64.

[0046] ST11-K64 Klebsiella pneumoniae removal of lipopolysaccharide:

[0047] The monoclonal colony of ST11-K64 Klebsiella pneumoniae was transferred to 30 ml LB medium and incubated at 37 °C for 6 h. The absorbance OD value at 600 nm was measured. According to the formula of McFarland turbidimetric tube OD value and corresponding bacterial concentration, the bacterial solution concentration was prepared to 1.0 × 10 9 From the sample with the number of bacteria / ml, the culture medium was removed, an equal amount of 100 mM EDTA was added, and the sample was incubated at 37°C for 60 min. The supernatant was removed by centrifugation, and the precipitate was washed three times with PBS buffer to obtain ST11-K64 Klebsiella pneumoniae with lipopolysaccharide removed.

[0048] Extraction and purification of ST11-K64 Klebsiella pneumoniae:

[0049] The wet weight of the ST11-K64 Klebsiella pneumoniae precipitate after removing lipopolysaccharide was roughly weighed, and PBS was added according to a solid-liquid ratio of 1:5 (mg / mL), and then 1 / 5 volume of 1% 3-sulfopropyl tetradecyl dimethyl betaine was added. After vortex mixing, the capsular polysaccharide was extracted in a water bath at 50°C for 60 minutes. After the extraction, the supernatant was obtained by centrifugation at 4000g, and 1 / 5 volume of chloroform-n-butanol mixture was added. The mixture was mixed and incubated in the dark for 30 minutes, centrifuged at 4000g for 15 minutes, and the upper aqueous phase was taken. Five times the volume of anhydrous ethanol was added, and the capsular polysaccharide was precipitated at 4°C for 48 hours. The ethanol was removed by centrifugation at 14000g / min for 20 minutes. The capsular polysaccharide precipitate was dissolved with 30 ml of sterile water, and then dialyzed for 48 hours through a dialysis bag (molecular weight cutoff 8000-14000Da). The dialysate was freeze-dried to obtain capsular polysaccharide. polysaccharide, CPS), named ST11-K64-CPS.

[0050] Example 2

[0051] The Klebsiella pneumoniae strain used for identification was ST11-K64:

[0052] The genome sequence of the strain was obtained by whole genome sequencing, and the MLST typing of the strain was analyzed using mlst software (v38) with reference to the PubMLST database, and it was found to be ST11. Using the K-PAM online database, the wzi gene sequence in the genome sequence of the strain was entered into the prediction database, and the capsule type of the strain was identified as K64.

[0053] ST11-K64 Klebsiella pneumoniae removal of lipopolysaccharide:

[0054] The monoclonal colony of ST11-K64 Klebsiella pneumoniae was transferred to 30 ml LB medium and incubated at 37 °C for 6 h. The absorbance OD value at 600 nm was measured. According to the formula of McFarland turbidimetric tube OD value and corresponding bacterial concentration, the bacterial solution concentration was prepared to 1.0 × 10 9 From the sample with the number of bacteria / ml, the culture medium was removed, an equal amount of 50 mM EDTA was added, and the mixture was incubated at 37°C for 30 min. The supernatant was removed by centrifugation, and the precipitate was washed three times with PBS buffer to obtain ST11-K64 Klebsiella pneumoniae with lipopolysaccharide removed.

[0055] Extraction and purification of ST11-K64 Klebsiella pneumoniae:

[0056] Roughly weigh the wet weight of the ST11-K64 Klebsiella pneumoniae precipitate after removing lipopolysaccharide, add PBS at a solid-liquid ratio of 1:5 (mg / mL), then add 1 / 5 volume of 1% (w / v) 3-sulfopropyltetradecyl dimethyl betaine, vortex mix, incubate in a 50°C water bath for 30 minutes to extract capsular polysaccharides, centrifuge at 4000g after extraction to obtain the supernatant, then add 1 / 5 volume of chloroform-n-butanol (5:1) mixture, mix well and protect from light. Incubate for 30 minutes, repeat the treatment three times, centrifuge at 4000g for 15 minutes, take the upper aqueous phase, add five times the volume of anhydrous ethanol, let stand at 4°C for 48 hours to precipitate capsular polysaccharide, centrifuge at 14000g / min for 20 minutes to remove ethanol, dissolve the capsular polysaccharide precipitate with 30 ml of sterile water, and then dialyze through a dialysis bag (molecular weight cutoff 8000-14000Da) for 48 hours. The dialysate is freeze-dried to obtain capsular polysaccharide (CPS), named ST11-K64-CPS.

[0057] Test Example 1

[0058] Purity identification and component analysis of ST11-K64 Klebsiella pneumoniae capsular polysaccharide:

[0059] 5 mg of capsular polysaccharide sample was accurately weighed and dissolved in 1 ml of 0.05 mol / L NaCl solution to prepare a 5 mg / ml solution. The solution was centrifuged at 8000 g for 10 min, and the supernatant was filtered with a 0.22 μm microporous filter membrane. The sample was then transferred to a 1.8 ml injection vial and tested for purity by high performance gel permeation chromatography. The purity of the capsular polysaccharide sample obtained was 97.264% ( Figure 2 ). Ion chromatography setting parameters: flow rate 0.6ml / min, column temperature 40ºC, injection volume 25µL.

[0060] Take 17 kinds of standards (fucose, rhamnose, arabinose, galactose, glucose, xylose, mannose, fructose, ribose, galacturonic acid, glucuronic acid, galactosamine hydrochloride, glucosamine hydrochloride, N-acetyl-D-glucosamine, guluronic acid, mannuronic acid, 2-keto-3-deoxyoctanoic acid), and prepare equal concentration standard solutions of each monosaccharide as mixed standards. Take 200ul of 5mg / ml capsular polysaccharide sample and add 2ml 3mol / L trifluoroacetic acid. After high temperature hydrolysis at 120℃ for 3 hours, transfer to a new tube and blow dry, add 1ml sterile water to reconstitute, and use ion chromatography to analyze the monosaccharide composition of the hydrolyzed capsular polysaccharide. The ion chromatography setting parameters are: flow rate 0.3ml / min, injection volume 5µL, column temperature 30 ºC.

[0061] Test Example 2

[0062] Molecular structure analysis of ST11-K64 Klebsiella pneumoniae capsular polysaccharide: The capsular polysaccharide dry powder was subjected to a series of techniques such as uronic acid reduction, methylation, hydrolysis, acetylation, NMR, and nuclear magnetic resonance analysis to obtain the structure of the polysaccharide.

[0063] Uronate reduction: 5 mg of capsular polysaccharide was reconstituted in sterile water, and then a uronic acid activator was added to adjust the pH to 4.6 and allowed to stand for 3 hours. The pH was then adjusted to 6.8 and allowed to stand for 2 hours. The capsular polysaccharide was then dialyzed and concentrated using a 1000Da dialysis bag. The uronic acid reduction experiment was repeated 3 times, and the dry powder was freeze-dried for monosaccharide composition testing.

[0064] Methylation analysis: 5 mg of capsular polysaccharide was added to 1 mL of DMSO and then quickly added to the solution A in the methylation kit (according to the kit instructions). After ultrasonic dissolution, the solution B in the methylation kit was added. The mixture was incubated in a 30°C water bath for 1 hour and 2 mL of sterile water was used to terminate the methylation reaction.

[0065] Hydrolysis + acetylation: Add 1ml 2mol / L trifluoroacetic acid to the methylated capsular polysaccharide for 90min, evaporate to dryness to obtain dry powder, then add 2ml sterile water to reconstitute, use 60mg sodium borohydride to treat for 8 hours, add an equal amount of glacial acetic acid to neutralize, dry at 101℃ to obtain dry powder, then add 1ml acetic anhydride to acetylate, react at 100℃ for 1 hour, cool to room temperature, add 3mL toluene, concentrate and evaporate to dryness under reduced pressure, repeat adding toluene 4 times and evaporate to dryness. Detection of internal connection mode of polysaccharide: Dissolve the acetylated capsular polysaccharide dry powder with 3mL dichloromethane, transfer to a separatory funnel, add 1ml sterile water and mix thoroughly, remove the upper aqueous solution, add 1ml sterile water and repeat 4 times, then mix the dichloromethane layer with an equal amount of anhydrous sodium sulfate, and finally adjust the volume to 10mL, and use gas chromatography-mass spectrometry to detect the internal connection mode of polysaccharide.

[0066] NMR analysis: 50 mg of capsular polysaccharide powder was repeatedly dissolved in 0.5 ml of heavy water and freeze-dried three times, and finally redissolved in heavy water. The obtained sample was analyzed using a nuclear magnetic resonance instrument at 25°C. The obtained nuclear magnetic data were analyzed using Topspin4.1.3 software to obtain 1H NMR spectrum, 13C NMR spectrum, DEPT135 one-dimensional spectrum and two-dimensional spectrum. Finally, combined with methylation analysis, the molecular structure of ST11-K64-CPS was inferred according to the ratio of glycosidic bonds and two-dimensional nuclear magnetic analysis.

[0067] like Figure 3 As shown, after uronic acid reduction, the extracted capsular polysaccharide ST11-K64-CPS is mainly composed of rhamnose, glucose and mannose, with a molar ratio of 0.2:0.583:0.217.

[0068] like Figure 4-Figure 7As shown, the results of the capsular polysaccharide ST11-K64-CPS methylated polysaccharide acetyl ester (PMAA) analyzed the internal connection mode of the polysaccharide:

[0069] Figure 4 a. The methylated sugar is 2,3,4-Me3-Rhap, and its mass fragments (m / z) are 45, 58, 72, 89, 101, 117, 131, 159, and the connection mode is Rhap-(1→;

[0070] Figure 4 b. The methylated sugar is 2,4-Me2-Rhap, and its mass fragments (m / z) are 45, 58, 85, 89, 99, 117, 127, 131, 159, 201, and the connection mode is →3)-Rhap-(1→;

[0071] Figure 4 c. The methylated sugar is 2,3,4,6-Me4-Glcp, its mass fragments (m / z) are 45,71,87,101,117,129,145,161,205, and the connection mode is Glcp-(1→;

[0072] Figure 5 a. The methylated sugar is 2,3,4,6-Me4-Manp, its mass fragments (m / z) are 45,71,87,101,117,129,145,161,205, and the connection mode is Manp-(1→;

[0073] Figure 5 b. The methylated sugar is 3-Me1-Rhapp, and its mass fragments (m / z) are 45, 87, 101, 117, 131, 161, 191, and the connection mode is →2,4)-Rhap-(1→;

[0074] Figure 5 c. The methylated sugar is 2,4,6-Me3-Glcp, and its mass fragments (m / z) are 45,87,99,101,117,129,161,173,233, and the connection mode is →3)-Glcp-(1→;

[0075] Figure 6 a. The methylated sugar is 2,3,6-Me3-Glcp, and its mass fragments (m / z) are 45,87,99,101,113,117,129,131,161,173,233, and the connection mode is →4)-Glcp-(1→;

[0076] Figure 6 b. The methylated sugar is 2,3,4-Me3-Manp, and its mass fragments (m / z) are 45,71,87,99,101,117,129,159,161, and the connection mode is →6)-Manp-(1→;

[0077] Figure 6 c. The methylated sugar is 2,6-Me2-Glcp, its mass fragments (m / z) are 45,87,97,117,159,185, and the connection mode is →3,4)-Glcp-(1→;

[0078] Figure 7 a. The methylated sugar is 2,3-Me2-Glcp, and its mass fragments (m / z) are 45,71,85,87,99,101,117,127,159,161,201,261, and the connection mode is →4,6)-Glcp-(1→;

[0079] Figure 7 b. The methylated sugar is 3,4-Me2-Manp, its mass fragments (m / z) are 45,87,99,129,189, and the connection mode is →2,6)-Manp-(1→.

[0080] like Figure 8-Figure 12 As shown, the structural analysis of the extracted capsular polysaccharide ST11-K64-CPS:

[0081] Figure 8 a. 1H NMR spectrum signals are mainly concentrated between 3.0 and 5.5 ppm, δ3.2-4.0 ppm is the sugar ring proton signal, and the main terminal proton peaks δ5.15, 5.14, 5.13, 5.07, 4.90, 4.66, 4.65, 4.58, 4.57, 4.36, and 4.33 are concentrated in the 4.3-5.5 ppm region.

[0082] Figure 8 b. 13C NMR spectrum analysis shows that the nuclear magnetic carbon spectrum signals are mainly concentrated between 60-120ppm. By observing the carbon spectrum, it can be seen that the main anomeric carbon signal peak is between δ93~105.

[0083] Fig. 9a. Dept135 spectrum analysis in the figure, the peaks at 67.92, 66.07, 65.76, 62.59, 62.37, 62.32, 62.09, and 61.99 ppm are inverted peaks, indicating a chemical shift of C6, and the peaks at 67.92, 66.07, and 65.76 ppm migrate to the low field, indicating the presence of substitution.

[0084] Fig. 9 b in Fig.10 a in Fig.10 b in Fig.11 . The anomeric carbon signal and the corresponding anomeric hydrogen signal position were observed through HSQC spectra, and the attribution of all glycosidic bond signals was analyzed by combining HH-COSY, HMBC and NOESY spectra. Combined with the results of polysaccharide methylated sugar alcohol acetyl ester analysis, the molecular structure of ST11-K64-CPS was inferred based on the ratio of glycosidic bonds and NMR two-dimensional analysis.

[0085] Fig.12 The molecular structure of ST11-K64-CPS is different from the CPS structure reported in the K-PAM database. The main chain and side chain of the isolated and identified CPS structure contain a large amount of glucose, and the mannose content in the main chain is also abnormally increased. Therefore, ST11-K64-CPS is a new type of capsular polysaccharide.

[0086] Preparation of ST11-K64-CPS solvent: Dissolve 2 mg of freeze-dried ST11-K64 Klebsiella pneumoniae capsular polysaccharide ST11-K64-CPS in 1 mL of PBS to prepare a 2 mg / mL solvent, which is used immediately upon preparation and stored in a -20°C refrigerator.

[0087] Test Example 3

[0088] Effect of ST11-K64-CPS solvent-induced sepsis mouse model - median lethal dose (LD50) test:

[0089] ① Experimental design

[0090] 40 C57BL / 6J male mice aged 5-6 weeks were selected and randomly divided into 4 groups, with 10 mice in each experimental group. Each group was injected with ST11-K64-CPS at a dose of 40 mg / kg (experimental group 1), 20 mg / kg (experimental group 2), 10 mg / kg (experimental group 3), and 5 mg / kg (experimental group 4). The experimental period was 5 days, and the mice were raised with reference to SPF mice. The animal experiment scheme involved in the patent of this invention has been approved by the Animal Ethics Committee of Jinling Hospital Affiliated to Nanjing University Medical School (Eastern Theater General Hospital).

[0091] ② Rearing conditions

[0092] The temperature was maintained at 22-25℃, the humidity was maintained at 45%-65%, a 12-h light / 12-h dark cycle was used, standard mouse pellet feed was provided, sterile drinking water was provided, and mouse bedding and drinking water were changed regularly to avoid contamination.

[0093] ③ Statistics of median lethal dose (LD50) in mice

[0094] Taking intraperitoneal injection of ST11-K64-CPS solvent as the starting point, the number of deaths of mice in each group was counted every 24 hours and observed for 5 consecutive days. The LD50 value was calculated using SPSS22 software, and the mouse survival curve was drawn using Graphpad 8.0. Each group of data was tested in parallel three times and the average value was taken, which was expressed as "mean ± standard deviation".

[0095] ④Test results

[0096] ST11-K64-CPS induced a mouse sepsis model, and the lethality of mice is shown in Table 1 and Fig.13 As shown, 3 mice died on the first day in the 40 mg / kg group, and 2 mice died on the second day; 1 mouse died on the first day in the 20 mg / kg group, and 2 mice died on the second day; no mice died in the 10 mg / kg group and the 5 mg / kg group. After 3 biological repetitions, the mortality rate of 20 mg / kg was about 26.67%, and the mortality rate of 40 mg / kg was about 53.33%. This shows that ST11-K64-CPS can induce the mouse death phenotype of the mouse sepsis model.

[0097] Table 1. Lethality of ST11-K64-CPS in mouse sepsis model

[0098]

[0099] Test Example 4

[0100] Effect of ST11-K64-CPS solvent-induced sepsis mouse model - immune inflammatory response detection:

[0101] ① Experimental design

[0102] Twelve C57BL / 6J male mice aged 5-6 weeks were randomly divided into two groups, with 6 mice in each experimental group, one group was the control group injected with PBS, and the other group was the experimental group injected with 40 mg / kg ST11-K64-CPS. The feeding conditions were the same as above.

[0103] ②Statistics of inflammatory immune response data of sepsis mice

[0104] Taking intraperitoneal injection of ST11-K64-CPS solvent as the starting point, blood was collected from the eye sockets 12 hours later, and the mouse blood was divided into two parts, one part was used to collect whole blood with an anticoagulant tube, and the other part was used to collect serum with a non-anticoagulant tube. Whole blood was used to detect the level of white blood cells in the blood, and serum was used to detect the inflammatory factors IL-6, IL-1β and TNF-α in the blood. The level of inflammatory factors was detected using IL-1β, IL-6 and TNF-α ELISA kits, and the serum levels of inflammatory cytokines were measured by ELISA method. Graphpad 8.0 was used to draw tables and graphs. Each group of data was subjected to three parallel experiments and the average value was taken, expressed as "mean ± standard deviation". The t-test was used between two groups, and variance analysis was used for three groups or more. p <0.05 indicated a significant difference.

[0105] ③Test results

[0106] ST11-K64-CPS induced mouse sepsis model, and the inflammatory immune response of mice was Fig.14 As shown, compared with the control group, ST11-K64-CPS induced a decrease in the level of leukocytes in the blood of mice, a decrease in the proportion of lymphocytes in various types of leukocytes, an increase in the proportion of neutrophils, monocytes, macrophages, eosinophils and basophils, and a significant increase in the levels of sepsis-related inflammatory factors IL-6, IL-1β and TNF-α in the blood, indicating that ST11-K64-CPS can induce an inflammatory immune response in the mouse sepsis model.

[0107] Test Example 5

[0108] Effect of ST11-K64-CPS solvent-induced sepsis mouse model - detection of organ tissue damage:

[0109] ① Experimental design

[0110] Twelve C57BL / 6J male mice aged 5-6 weeks were randomly divided into two groups, with 6 mice in each experimental group; one group was the control group injected with PBS, and the other group was the experimental group injected with 40 mg / kg ST11-K64-CPS. The feeding conditions were the same as above.

[0111] ②Evaluation of organ and tissue damage in septic mice

[0112] The mice were killed by cervical dislocation 12 hours after intraperitoneal injection of ST11-K64-CPS solvent. The heart, lung, liver, pancreas, spleen and kidney tissues were removed and fixed in 10% neutral buffered formalin solution for 24 hours, and then H&E staining was performed according to the common technical methods in the field. HE-stained sections were observed under an optical microscope. Ten high-magnification (200x) fields of view were randomly selected for each tissue. Three independent readers scored according to the following scoring criteria, and the average value was taken as the final pathological score of each mouse. Pancreatic tissue was scored according to the Schmid scoring standard, lung tissue was scored according to the Smith scoring standard, liver tissue was scored according to the Ishak scoring standard, kidney tissue was scored according to the Schmidt scoring standard, heart tissue was scored according to the Chiharu scoring standard, and spleen tissue was scored according to the Giamarellos-Bourboulis scoring standard. Each group of data was averaged after three parallel experiments, expressed as "mean ± standard deviation", t-test was used between two groups, and variance analysis was used for three groups or more. p <0.05 indicated a significant difference.

[0113] ③Test results

[0114] ST11-K64-CPS induced a mouse sepsis model, and the damage to mouse organs and tissues is shown in Table 2 and Fig.15 As shown, compared with the control group, ST11-K64-CPS induced pathological damage in the important organs (heart, lung, liver, pancreas, spleen and kidney) of septic mice (p<0.05), which is similar to the multi-organ damage in human sepsis patients, indicating that ST11-K64-CPS can induce multi-organ damage in the mouse sepsis model.

[0115] Table 2. Damage to important organs and tissues in the ST11-K64-CPS-induced sepsis mouse model

[0116]

[0117] The above results show that ST11-K64-CPS can induce mouse death, inflammatory immune response in the blood, and pathological damage to organ tissues, thereby simulating the pathophysiological changes of the occurrence and development of human sepsis in mice. Therefore, it can be widely used as a biological inducer in the field of basic research on sepsis.

[0118] The above are only preferred embodiments of the present invention, which are helpful for those skilled in the art to further understand the present invention, but do not limit the present invention in any form. It should be pointed out that for those skilled in the art, several modifications and improvements made without departing from the concept of the present invention are all protected by the present invention.

Claims

1. A capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae, characterized in that The molecular structure of the capsular polysaccharide is: 。 2. The capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae according to claim 1, characterized in that The monosaccharide composition of the capsular polysaccharide after uronic acid reduction is rhamnose, glucose and mannose; the molar ratio of rhamnose, glucose and mannose is 0.200:0.583:0.

217.

3. Use of the capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae according to any one of claims 1 to 2 in preparing a mouse sepsis model.

4. The use of the capsular polysaccharide of ST11-K64 type Klebsiella pneumoniae according to claim 3 in preparing a mouse sepsis model, characterized in that: 2 mg of capsular polysaccharide dry powder was dissolved in 1 ml of PBS and mixed to obtain 2 mg / ml solvent, which was routinely stored at -20°C. 40 mg / kg of solvent was injected intraperitoneally into each mouse, and a mouse sepsis model was obtained 12 hours later.

Citation Information

Patent Citations

  • Klebsiella pneumoniae capsule polysaccharide vaccines

    CN110290804A

  • Polysaccharide protein conjugates

    CN116688109A

  • Klebsiella pneumoniae capsule polysaccharide vaccines

    US20200038497A1

  • Bacteriophage(s) targeting capsular deficient klebsiella pneumoniae (KP), compositions comprising it(THEM) and use(s) thereof

    WO2024013350A1